Clover Doses First Participants in Phase III Trial Evaluating SCB-2019 as a Heterologous COVID-19 Booster Following Prior Vaccination with Inactivated, mRNA or Viral Vector Vaccines

Clover Biopharmaceuticals, Ltd. announced the first participants have been dosed in a Phase III study evaluating the safety and immunogenicity of Clover’s SCB-2019 vaccine candidate as a COVID-19 booster in individuals who previously vaccinated with CoronaVac™, Comirnaty®, or Vaxzevria®.